LAUREN DUFOUR: Open Payments
NPI 1508408477 · MANDEVILLE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,742 in 56 payments from 24 companies in 2025. Trend: 2023 $824 · 2024 $1,610 · 2025 $2,742
Food & beverage: $2,742
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $372 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $362 |
| ABBVIE INC. | 4 | $276 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $180 |
| AstraZeneca Pharmaceuticals LP | 3 | $159 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 4 | $149 |
| Edwards Lifesciences Corporation | 1 | $142 |
| Novartis Pharmaceuticals Corporation | 1 | $139 |
| Actelion Pharmaceuticals US, Inc. | 1 | $122 |
| Exact Sciences Corporation | 2 | $116 |
Products named: CAPLYTA, Wegovy, Kerendia, XIFAXAN, QULIPTA, LEQVIO, Ozempic, UPTRAVI.
Industry payments across LA — which companies pay providers there.
